Truist has officially taken over the coverage of Vertex Pharmaceuticals, assigning a buy rating to the company's stock, particularly in relation to its kidney drug portfolio. This move indicates Truist's confidence in Vertex's potential for growth and success in the renal therapeutics market. The decision reflects an analysis of Vertex's ongoing developments and innovations in treatments for kidney diseases.
Related Articles
Don't miss out on breaking stories and in-depth articles.